[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP: Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol; 2010 Sep;222(1):110-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.
  • The 'p53 signature' is a benign secretory cell outgrowth in the distal Fallopian tube that shares properties with ovarian serous cancer-including p53 mutations-and is a putative serous cancer precursor.
  • SCOUTs were prevalent in both proximal and distal tube and significantly associated with serous carcinoma versus the others (p < 0.001); 89% were PAX2 (A) and 26% were PAX2 (A)/p53 (A) (p53 signatures).
  • SCOUTs are discretely localized alterations commonly containing altered expression of multiple genes within histologically benign tubal epithelium.
  • Geographic distribution in the tube varies by genotype and immunophenotype, from regionally unrestricted (PAX2) to greater likelihood specific area (fimbria) of shared prevalence (PAX2 and p53).
  • This study reveals, for the first time, an entity (SCOUT) that is associated with serous cancer, expands the topography of altered PAX2 expression in the female genital tract mucosa and highlights another potential pathway disturbance involved in early serous carcinogenesis in the Fallopian tube.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):58-64 [19258943.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1243-50 [19525924.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1133-8 [19543244.001]
  • [Cites] Int J Gynecol Pathol. 2009 Nov;28(6):570-8 [19851209.001]
  • [Cites] Oncogene. 2010 Feb 25;29(8):1103-13 [19935705.001]
  • [Cites] Mod Pathol. 2010 Oct;23(10):1316-24 [20562848.001]
  • [Cites] Mod Pathol. 2011 Jan;24(1):152-6 [20871594.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):20-30 [12538447.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):109-20 [12649664.001]
  • [Cites] Science. 1983 Nov 18;222(4625):771-8 [6356358.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1550-9 [8155119.001]
  • [Cites] Med Pediatr Oncol. 1996 Nov;27(5):440-4 [8827071.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3114-20 [9853867.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • (PMID = 20597068.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / P50 CA105009; United States / NIGMS NIH HHS / GM / R01 GM083348; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS207936; NLM/ PMC2914810
  •  go-up   go-down


2. Xian W, Miron A, Roh M, Semmel DR, Yassin Y, Garber J, Oliva E, Goodman A, Mehra K, Berkowitz RS, Crum CP, Quade BJ: The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol; 2010 Jan;220(1):17-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
  • A candidate early precursor to pelvic serous cancer, the 'p53 signature', is commonly found in the benign mucosa of the distal Fallopian tube and harbours p53 mutations and evidence of DNA damage.
  • Fallopian tubes from two cases of LFS were immunostained for p53, Ki-67 (proliferation) and H2AX (DNA damage response) and analysed for p53 mutations by laser capture microdissection (LCM) and p53 genomic sequencing (exons 2-11).
  • The LFS model confirms prior observations that the distal Fallopian tube is particularly prone to focal epithelial p53 gene inactivation-p53 mutation and LOH-in the absence of malignancy or increased epithelial proliferation.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Mol Med Today. 1997 Sep;3(9):390-5 [9302689.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Cell. 2007 May 4;129(3):523-36 [17482546.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] BMC Cancer. 2008;8:17 [18208621.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1337-44 [18483220.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Pediatr Radiol. 2009 Feb;39 Suppl 1:S27-31 [19083227.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):731-5 [19221485.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3625-33 [19336573.001]
  • [Cites] Histopathology. 2001 May;38(5):481-2 [11422490.001]
  • [Cites] In Vivo. 1999 Jan-Feb;13(1):99-106 [10218141.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Fam Cancer. 2009;8(4):339-46 [19340607.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):787-95 [11550149.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):157-62 [11905807.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [CommentIn] J Pathol. 2010 Jan;220(1):5-6 [19882674.001]
  • (PMID = 19834951.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / 1R21CA124688-01A1; United States / NCI NIH HHS / CA / P50CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS184416; NLM/ PMC2841524
  •  go-up   go-down


3. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This has led to the proposal that ovarian cancer develops de novo.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.


Advertisement
4. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol; 2005 Dec;18(12):1618-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed an immunocytochemical survey of XIAP expression in cell blocks from benign and malignant body cavity effusions and washes.
  • The prevalence of staining for specific malignancies varied with the tissue of origin as follows: ovarian (13/13, 100%); lung (9/11, 82%), breast (6/13, 46%); gastric (4/7, 57%), colon (0/4, 0%), pancreas (2/3, 67%), gallbladder (1/1, 100%), fallopian tube (1/3, 33%), endometrial (6/7, 86%), mesothelioma (4/5, 80%), carcinoma of unknown primary (5/5, 100%) and hematopoietic malignancies (3/9, 33%).
  • Benign effusions (n = 35) were virtually XIAP-negative except for two cases (6%) in which histiocytes showed moderate staining.
  • XIAP immunostaining, when strong, allows for ready distinction of malignant from benign and reactive cell populations.
  • The degree of XIAP staining of tumor cells may be a means of identifying the most therapy-resistant cases (ie, those with strong XIAP expression), and allow additional triaging to XIAP-blocking drugs presently being developed and clinically tested.
  • [MeSH-major] Ascitic Fluid / chemistry. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Peritoneal Lavage. Pleural Effusion, Malignant / chemistry. X-Linked Inhibitor of Apoptosis Protein / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118627.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


5. Levanon K, Crum C, Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol; 2008 Nov 10;26(32):5284-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One such dogma is the adenoma-carcinoma sequence and that a multistep accumulation of genetic alterations is required for transformation from a benign to a neoplastic tissue.
  • The inevitable derivative of this dogma is that every invasive carcinoma is in fact a missed intraepithelial tumor, and furthermore, a late evolutionary stage in the sequence of development from a precursor lesion.
  • In this article, we discuss the emergence of the fallopian tube fimbria as a field of origin for high-grade serous carcinomas and present a binary model of ovarian cancer pathogenesis that takes into consideration prior epidemiologic, morphologic, and genetic data.
  • With the rise of the fallopian tube secretory epithelial cell as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model systems to characterize the biology and physiology of this cell is recognized.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 1997 Jul;16(3):250-5 [9421091.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86 [9839517.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3114-20 [9853867.001]
  • [Cites] Gynecol Obstet Invest. 1999;47(1):45-51 [10026026.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):151-7 [10029442.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):626-8 [10203282.001]
  • [Cites] Hum Reprod. 1999 Jan;14(1):162-6 [10374114.001]
  • [Cites] Exp Mol Pathol. 1999 Jun;66(2):163-9 [10409445.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Surg Gynecol Obstet. 1951 Sep;93(3):327-30 [14866716.001]
  • [Cites] Obstet Gynecol Surv. 1961 Apr;16:209-26 [13749597.001]
  • [Cites] Am J Obstet Gynecol. 1950 Jan;59(1):58-67, illust [15399626.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Adv Cancer Res. 2005;93:159-87 [15797447.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1544-50 [10526284.001]
  • [Cites] Hum Reprod. 2000 Jul;15(7):1597-603 [10875873.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2728-32 [10894872.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):383-90 [10918170.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87 [10985881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1427-31 [11121643.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):176-80 [11161856.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1467-70 [11377596.001]
  • [Cites] Histopathology. 2001 May;38(5):481-2 [11422490.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1283-9 [11688463.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Ital J Anat Embryol. 2001;106(2 Suppl 2):263-76 [11732586.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):171-8 [11812938.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1609-15 [12023992.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72 [12237282.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):691-703 [12445245.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):228-32 [12569579.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Histopathology. 2003 Jul;43(1):26-32 [12823709.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Fam Cancer. 2003;2(2):73-8 [14574155.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):35-40 [14668548.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Mol Reprod Dev. 2004 Feb;67(2):243-50 [14694441.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9 [14984481.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):819-26 [14984947.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):476-82 [15863147.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):248-50 [16095676.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] Am J Obstet Gynecol. 2006 Jun;194(6):1702-9 [16731090.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11125-30 [17145855.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11565-70 [17178846.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):331-7 [17064757.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2990-3001 [17409405.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Br J Radiol. 2007 Sep;80 Spec No 1:S13-22 [17704321.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Histopathology. 2008 Aug;53(2):127-38 [18298580.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):52-6 [12468342.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):127-32 [15625367.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1329-37 [14996907.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1492-7 [15083174.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):615-25 [15171704.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1112-4 [15252324.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:70 [14609432.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1014-21 [15297969.001]
  • [Cites] Am J Obstet Gynecol. 2004 Sep;191(3):718-32 [15467531.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Am J Pathol. 1977 Jun;87(3):686-720 [194486.001]
  • [Cites] Obstet Gynecol Surv. 1979 Apr;34(4):257-70 [471364.001]
  • [Cites] Diagn Gynecol Obstet. 1981 Spring;3(1):49-60 [7215124.001]
  • [Cites] Am J Obstet Gynecol. 1983 Sep 1;147(1):1-6 [6614075.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):711-6 [6578366.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):717-21 [6578367.001]
  • [Cites] J Membr Biol. 1985;88(2):149-63 [4093958.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:35-51 [3665870.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):229-35 [2715297.001]
  • [Cites] Hum Reprod. 1989 Jul;4(5):486-94 [2794010.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):236-9 [2807017.001]
  • [Cites] Hum Reprod. 1990 Jan;5(1):25-31 [2182659.001]
  • [Cites] Hum Reprod. 1992 Sep;7(8):1144-9 [1400940.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Obstet Gynecol. 1993 Aug;82(2):181-6 [8336861.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Fertil Steril. 1994 Jun;61(6):1103-8 [8194625.001]
  • [Cites] N Engl J Med. 1994 Sep 22;331(12):771-6 [8065405.001]
  • [Cites] Biol Cell. 1994;82(2-3):103-7 [7606207.001]
  • [Cites] Biol Reprod. 1996 Feb;54(2):436-45 [8788197.001]
  • [Cites] Obstet Gynecol. 1996 Oct;88(4 Pt 1):554-9 [8841217.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] N Engl J Med. 1997 May 15;336(20):1401-8 [9145676.001]
  • (PMID = 18854563.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R21 CA12468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2652087
  •  go-up   go-down


6. Mondal SK: Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence. J Obstet Gynaecol Res; 2010 Jun;36(3):690-2
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence.
  • A rare coexistence of an adenofibroma and ectopic pregnancy in the left fallopian tube is reported.
  • Adenofibroma is a rare benign neoplasm of the fallopian tube, and the fallopian tube is the most common site of ectopic pregnancies.
  • However, coexistence of such rare tumor and ectopic pregnancy is extremely rare.
  • Placental tissue, consisting of chorionic villi and trophoblastic cells was present in the ampulla of fallopian tube.
  • [MeSH-major] Adenofibroma / complications. Adenofibroma / pathology. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Pregnancy, Tubal / pathology

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598059.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


7. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP: A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol; 2010 Sep;17(5):293-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube.
  • The fallopian tube has recently emerged as an important site of origin for not only early serous cancer in women with inherited mutations in BRCA1/BRCA2 but as a source of many pelvic serous carcinomas.
  • A modified protocol for sectioning the fallopian tube (SEE-FIM) is discussed and each of the above topics is covered in the context of its differential diagnosis and recommendations for reporting are included.
  • Finally, the rationale for close inspection of the tube, both in presumed benign and malignant disease, is discussed, with reference to an ongoing multi-institutional web-based project (Pelvic-ovarian Cancer Interception project).
  • [MeSH-major] Carcinoma in Situ / pathology. Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenofibroma / secretion. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Metaplasia. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20733351.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Varras M, Akrivis Ch, Tsoukalos G, Plis Ch, Karadaglis S, Ladopoulos I: Tubal ectopic pregnancy associated with an extraskeletal chondroma of the fallopian tube: case report. Clin Exp Obstet Gynecol; 2008;35(1):83-5
Genetic Alliance. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubal ectopic pregnancy associated with an extraskeletal chondroma of the fallopian tube: case report.
  • Extraskeletal chondroma is a relatively uncommon benign soft tissue tumor, which usually occurs in the hands and feet.
  • The tumor may also occur around the tendon, synovium, or joint capsule.
  • Chondroma of the fallopian tube is extremely rare, with only two reports in the English literature.
  • We present the first reported case of extraskeletal chondroma of the fallopian tube causing transportation impairment of the fertilized ovum in a 32-year-old gravida 1, para 1 woman.
  • [MeSH-major] Chondroma / complications. Fallopian Tube Neoplasms / complications. Pregnancy, Tubal / etiology

  • Genetic Alliance. consumer health - Chondroma.
  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18390091.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol; 2007 Feb;19(1):3-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The distal fallopian tube: a new model for pelvic serous carcinogenesis.
  • RECENT FINDINGS: The distal fallopian tube is emerging as an established source of many early serous carcinomas in women with BRCA mutations (BRCA+).
  • A candidate precursor to tubal intraepithelial carcinoma, entitled the 'p53 signature', suggests that molecular events associated with serous cancer (p53 mutations) may be detected in benign mucosa.
  • The emerging data offer compelling evidence for a model of 'fimbrial-ovarian' serous neoplasia, and call attention to the distal fallopian tube as an important source for this disease, the study of which could clarify pathways to cancer in both organs and generate novel strategies for cancer prevention.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Fallopian Tube Neoplasms / pathology. Genes, BRCA1. Peritoneal Neoplasms / etiology
  • [MeSH-minor] Carcinoma in Situ / etiology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic. Female. Humans. Ovarian Neoplasms / etiology. Ovarian Neoplasms / pathology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218844.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 43
  •  go-up   go-down


10. Gueth U, Renner R, Egelhof T, Singer G, Holzgreve W, Mayr J: Retroperitoneal displacement of ovary and fallopian tube: a complication of surgical management of incarcerated inguinal hernia in female infants. J Pediatr Surg; 2007 May;42(5):E33-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal displacement of ovary and fallopian tube: a complication of surgical management of incarcerated inguinal hernia in female infants.
  • We report a case of a 12-year-old girl presenting with a benign tumor (serous cystadenofibroma) in a retroperitoneally located ovary.
  • Displacement of the ovary and fallopian tube in the retroperitoneal space is a rarely reported complication of pediatric inguinal hernia surgery.
  • [MeSH-major] Fallopian Tubes / pathology. Hernia, Inguinal / complications. Hernia, Inguinal / surgery. Ovary / pathology
  • [MeSH-minor] Child. Contrast Media. Diagnosis, Differential. Female. Humans. Iatrogenic Disease. Laparoscopy. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502174.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


11. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol; 2007 Jan;211(1):26-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
  • Somatic p53 tumour suppressor gene mutations in these tumours suggest a pathogenesis involving DNA damage, p53 mutation, and progressive loss of cell cycle control.
  • We recently identified foci of strong p53 immunostaining-termed 'p53 signatures'-in benign tubal mucosa from BRCA+ women.
  • To examine the relationship between p53 signatures and TIC, we compared location (fimbria vs ampulla), cell type (ciliated vs secretory), evidence of DNA damage, and p53 mutation status between the two entities. p53 signatures were equally common in non-neoplastic tubes from BRCA+ women and controls, but more frequently present (53%) and multifocal (67%) in fallopian tubes also containing TIC.
  • [MeSH-major] Carcinoma in Situ / genetics. Cystadenocarcinoma, Serous / genetics. Fallopian Tube Neoplasms / genetics. Genes, Neoplasm. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Cyclin E / analysis. DNA Damage. Fallopian Tubes / pathology. Female. Genes, BRCA1. Genes, BRCA2. Genes, p53. Genetic Markers. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Microdissection. Mutation. Ovary / pathology. Polymerase Chain Reaction / methods. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • [ErratumIn] J Pathol. 2007 Sep;213(1):116
  • (PMID = 17117391.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83944; United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / P50 CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / Genetic Markers; 0 / Ki-67 Antigen
  •  go-up   go-down


12. Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ: Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations. Am J Surg Pathol; 2009 Jan;33(1):111-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
  • Germline mutations in the hereditary breast/ovary carcinoma genes BRCA1 or BRCA2 confer increased lifetime risk for ovarian, fallopian tube, and primary peritoneal carcinoma.
  • Transitional cell metaplasia is a benign epithelial alteration that is a common finding in the serosa of the tube but is underrecognized in the tubal fimbriae, where it may mimic tubal intraepithelial carcinoma.
  • Median tumor size was 2.7 mm (range: 1 to 11 mm).
  • No particular clinical variables (BRCA 1 vs. BRCA 2 mutation, parity, personal history of breast cancer, prior abdomino-pelvic surgery, or intraoperative findings) or benign pathologic alterations in the RRSO specimens were associated with the presence of transitional cell metaplasia of the fimbriae.
  • This study demonstrates that transitional cell metaplasia of the fimbriae is a common benign finding in RRSO specimens that should not be confused with the much less common finding of tubal intraepithelial carcinoma.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology. Genetic Predisposition to Disease
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Ovariectomy. Risk Factors. Tumor Suppressor Protein p53 / metabolism


13. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol; 2009 Dec;33(12):1878-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
  • Most occult cancer is localized in the fallopian tube fimbriae and is as small as 1 mm in size.
  • Recommended protocols to maximize tumor detection emphasize the role of thinly slicing the tubes and ovaries and embedding the entire specimen for microscopic examination.
  • No tubal carcinoma was identified in the level sections of any case originally classified as benign.
  • Clinical follow-up among women with benign RRSO findings revealed that 2 women subsequently developed peritoneal carcinomatosis at 22 and 62 months postoperatively.
  • Retrospective exhaustive multistep level sectioning of all remaining tubal and ovarian blocks from both these women confirmed the original benign diagnosis in 1 woman but in the other woman, the deepest levels of 1 ovarian block revealed a single 1-mm nodule of cancer at the base of an ovarian surface epithelial invagination.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Carcinoma / prevention & control. Dissection. Early Detection of Cancer. Fallopian Tube Neoplasms / prevention & control. Germ-Line Mutation. Ovariectomy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898224.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


14. Junaid I, Paz R, Salihu HM, Sharma PP, Aliyu ZY: Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors. Arch Gynecol Obstet; 2006 Feb;273(5):315-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors.
  • BACKGROUND: Meig's and Pseudo-Meig's syndromes have been reported in association with several malignancies but the concomitant existence of multiple synchronous benign and malignant tumors in association with Pseudo-Meigs' syndrome has not been reported in the published literature.
  • Histological examination confirmed a right ovarian carcinoid tumor embedded within a mature cystic teratoma while the left ovary, fallopian tube and the uterus contained a poorly differentiated adenocarcinoma of the endometrium.
  • CONCLUSION: This is the first case report of Pseudo-Meig's syndrome in association with ovarian carcinoid tumor and multiple synchronous benign and malignant pelvic tumors.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Asthma / complications. CA-125 Antigen / blood. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Hydrothorax / complications. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Uterine Neoplasms / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136360.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


15. Bunyavejchevin S, Phupong V: Laparoscopic surgery for presumed benign ovarian tumor during pregnancy. Cochrane Database Syst Rev; 2006;(4):CD005459
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for presumed benign ovarian tumor during pregnancy.
  • The procedures include resection of the tumor (enucleation), removal of an ovary or ovaries (oophorectomy), or surgical excision of the fallopian tube and ovary (salpingo-oophorectomy).
  • OBJECTIVES: To compare the effects of using laparoscopic surgery for benign ovarian tumor during pregnancy on maternal and fetal health and the use of healthcare resources.
  • SELECTION CRITERIA: Randomized controlled trials with reported data that compared outcomes of laparoscopic surgery for benign ovarian tumor in pregnancy to conventional laparotomy technique.
  • AUTHORS' CONCLUSIONS: The practice of laparoscopic surgery for benign ovarian tumour during pregnancy is associated with benefits and harms.
  • The available case series studies of laparoscopic surgery for benign ovarian tumour during pregnancy provide limited insight into the potential benefits and harms associated with this new surgical technique in pregnancy.
  • Randomized controlled trials are required to provide the most reliable evidence regarding the benefits and harms of laparoscopic surgery for benign ovarian tumour during pregnancy.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005459 [23440802.001]
  • (PMID = 17054259.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


16. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L: Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst; 2007 Nov 21;99(22):1706-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
  • BACKGROUND: Subjective evaluation of gray-scale and Doppler ultrasound findings (i.e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal (i.e., ovarian, paraovarian, or tubal) masses.
  • METHODS: In a prospective multicenter study--the International Ovarian Tumor Analysis--1066 women with a persistent adnexal mass underwent transvaginal gray-scale and color Doppler ultrasound examinations by an experienced examiner within 120 days of surgery.
  • Pattern recognition was used to classify a mass as benign or malignant.
  • RESULTS: Pattern recognition correctly classified 93% (95% confidence interval [CI] = 90.9% to 94.6%) of the tumors as benign or malignant.
  • Histologic diagnoses that were most often misclassified by CA-125 were fibroma, endometrioma, and abscess (false-positive results) and borderline tumor (false-negative results).
  • Pattern recognition correctly classified 86% (95% CI = 81.1% to 90.4%) of masses of these four histologic types as being benign or malignant, whereas a serum CA-125 at a cutoff of 30 U/mL correctly classified 41% (95% CI = 34.4% to 47.5%) of them.
  • Pattern recognition assigned a correct specific histologic diagnosis to 333 (59%, 95% CI = 54.5% to 62.8%) of the 567 benign lesions.
  • CONCLUSION: Pattern recognition was superior to serum CA-125 for discrimination between benign and malignant adnexal masses.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Fallopian Tube Neoplasms / immunology. Fallopian Tube Neoplasms / ultrasonography. Gynecology / manpower. Ovarian Neoplasms / immunology. Ovarian Neoplasms / ultrasonography. Pattern Recognition, Visual
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Adult. Aged. Diagnosis, Differential. Europe. Female. Humans. Middle Aged. Postmenopause. Predictive Value of Tests. Premenopause. Prospective Studies. Research Design. Sensitivity and Specificity. Ultrasonography, Doppler. Vagina

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000221.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


17. Salamon C, Tornos C, Chi DS: Borderline endometrioid tumor arising in a paratubal cyst: a case report. Gynecol Oncol; 2005 Apr;97(1):263-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline endometrioid tumor arising in a paratubal cyst: a case report.
  • BACKGROUND: Paratubal cysts, generally known as hydatid cysts of Morgagni, are small round cysts attached by a pedicle to the fimbriated end of the tube.
  • The following represents the first reported case of an endometrioid tumor of low malignant potential arising in a paratubal cyst.
  • All frozen-section diagnoses were benign; however, final pathology revealed a borderline tumor of low malignant potential of endometrioid type in the right paratubal cyst.
  • Final pathologic analysis revealed no evidence of persistent borderline tumor.
  • Laparoscopic surgery is an option in the management of adnexal masses; however, rupture or puncture of masses should be avoided when possible to prevent potential tumor dissemination in the event of a malignancy.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Cysts / complications. Fallopian Tube Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790473.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dai SY, Hata K, Inubashiri E, Kanenishi K, Shiota A, Ohno M, Yamamoto Y, Nishiyama Y, Ohkawa M, Hata T: Does three-dimensional power Doppler ultrasound improve the diagnostic accuracy for the prediction of adnexal malignancy? J Obstet Gynaecol Res; 2008 Jun;34(3):364-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the present study was to investigate the diagnostic accuracy of three-dimensional power Doppler ultrasound (3DPD) in the differentiation between benign and malignant adnexal masses and evaluate 3DPD for assessing malignancy in comparison with two-dimensional transvaginal gray-scale sonography (2DTVS), magnetic resonance imaging (MRI) and positron emission tomography (PET).
  • Final diagnosis was confirmed by the postoperative histopathology.
  • RESULTS: Of the 36 patients, 25 had a malignancy, 5 had a borderline tumor, and 6 had a benign mass.
  • [MeSH-major] Adnexal Diseases / diagnosis. Genital Neoplasms, Female / diagnosis. Ultrasonography, Doppler / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fallopian Tube Neoplasms / diagnosis. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686352.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP: Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol; 2006 Jan;13(1):1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prophylactic salpingo-oophorectomies from women with BRCA mutations (BRCA+) have identified the tube as a frequent site of early pelvic serous carcinoma (tubal intraepithelial carcinoma [TIC]).
  • This review addresses a multitude of epithelial changes; benign, malignant, and an intriguing third group, which we term "p53 signatures," is found in benign, nonciliated epithelium and stain intensely positive for p53.
  • [MeSH-major] Carcinoma in Situ / pathology. Fallopian Tube Neoplasms / pathology. Mass Screening / methods. Ovarian Neoplasms / etiology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Proliferation. Epithelium / chemistry. Epithelium / pathology. Fallopian Tubes / chemistry. Fallopian Tubes / cytology. Fallopian Tubes / pathology. Female. Gene Expression Regulation, Neoplastic. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Humans. Ovariectomy. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462151.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 31
  •  go-up   go-down


20. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


21. McCluggage WG: Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol; 2010 Mar;17(2):122-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcoma is an uncommon, but not rare, mixed tumor containing a neoplastic but benign or mildly atypical epithelial element and a sarcomatous, usually low-grade, stromal component.
  • The most common site is the uterine corpus but adenosarcoma also occurs in the cervix and ovary and more rarely in the vagina, fallopian tube, arising from peritoneal surfaces, or outside the female genital tract, for example in the intestine.
  • Characteristic histologic features include a low power "phyllodes-like" architecture with leaf-like projections lined by a variety of benign Mullerian type epithelia, sometimes with squamous metaplasia.
  • Using the World Health Organization definition, stromal mitotic activity of 2 or more per 10 high-power fields is required for a diagnosis of adenosarcoma but in practice the diagnosis is made with stromal mitotic activity less than this if the characteristic architecture and cambium layer is present.
  • Adenosarcoma may be confused with a variety of lesions and one of the main differential diagnoses is adenofibroma in which the stromal component is, by definition, morphologically benign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179434.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


22. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML: Validation of referral guidelines for women with pelvic masses. Obstet Gynecol; 2005 Jan;105(1):35-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the guidelines are evidence-based, their predictive value in distinguishing cancers from benign masses is unknown.
  • RESULTS: A total of 1,035 patients were identified, including 318 (30.7%) with primary malignancies of the ovary, fallopian tube, or peritoneum.
  • Fifty additional patients (4.8%) had cancers metastatic to the ovaries, and the remaining 667 (64.4%) had benign masses.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. CA-125 Antigen / analysis. Female. Gynecology. Humans. Medical Oncology. Middle Aged. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Postmenopause. Practice Guidelines as Topic. Premenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625139.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


23. Wang JH, Wu DH, Jin H, Wu YZ: Predominant etiology of adnexal torsion and ovarian outcome after detorsion in premenarchal girls. Eur J Pediatr Surg; 2010 Sep;20(5):298-301
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of all torsive ovaries, histopathology verified that 2 (3.0%) cases were malignant, 8 (12.1%) cases were normal, and 56 (84.9%) cases were benign.
  • CONCLUSIONS: Premenarchal girls with adnexal torsion more commonly had a benign ovarian tumor or no underlying abnormality as an etiology; ovarian malignancy was rare.
  • [MeSH-major] Fallopian Tube Diseases / etiology. Ovarian Diseases / etiology. Torsion Abnormality / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20533130.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Zhai QJ, Ozcan A, Hamilton C, Shen SS, Coffey D, Krishnan B, Truong LD: PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):323-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors.
  • Among the non-neoplastic tissue, PAX-2 was expressed in glomerular parietal epithelial cells, renal collecting duct cells, atrophic renal tubular cells, epithelial cells of ovarian surface, fallopian tube, endocervix, endometrium, seminal vesicle, and lymphocytes.
  • Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216401.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


25. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol; 2010 Aug 1;118(2):189-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovarian cancers, normal ovaries, benign ovarian neoplasms, and fallopian tube fimbria.
  • RESULTS: EVI1 and EVI1s mRNAs were ubiquitously expressed in ovarian cancers and benign gynecologic tissues examined, with highest expression of both isoforms noted in the cancer samples.
  • EVI1 protein expression patterns were similar between serous ovarian cancer samples, fallopian tube fimbria, and benign neoplasms.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cisplatin / pharmacology. DNA Damage. Drug Delivery Systems. Female. Gene Knockdown Techniques. Humans. Middle Aged. Protein Isoforms. Proto-Oncogenes / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20462630.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Guo DH, Pang SJ, Shen Y: [Atypical endometriosis: a clinicopathologic study of 163 cases]. Zhonghua Fu Chan Ke Za Zhi; 2008 Nov;43(11):831-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathologic changes of AEM including its glandular epithelium, stroma, background and the conditions coexisting with tumor were observed.
  • Of 172 AEM foci of 163 patients, 168 were in the ovary, and the other 4 were in the fallopian tube, cervix and uterine serosa respectively.
  • AEM associated with tumour was found in 26 cases (15.95%) and among 27 of ovarian AEM, 15 were malignant, 9 borderline and 3 benign.
  • The transformation from AEM to tumor was found in most of the malignant tumors (14/15, 93%).
  • CONCLUSIONS: AEM lesions hold some features of both EM and tumor, which may have a relatively higher potential for tumorigenesis and canceration.
  • The process of damage and repair in EM foci during a long course may play a role in the development of EM into AEM and finally into tumor.
  • [MeSH-minor] Adenosarcoma / complications. Adenosarcoma / epidemiology. Adenosarcoma / pathology. Adolescent. Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087566.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Manjunath GV, Nandini NM, Sunila: Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature. Indian J Pathol Microbiol; 2005 Oct;48(4):503-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature.
  • They also occur in uterus, fallopian tube, and ovary.
  • These benign tumours are asymptomatic or cause mild symptoms and a palpable mass.
  • Fine needle aspiration of these tumours is very useful to differentiate malignant from benign lesions and helps to avoid unnecessary aggressive surgical procedures.
  • FNAC of these benign epididymal tumours is diagnostic, rapid, reliable, conclusive and cost effective.
  • We are reporting a case of adenomatoid tumour of epididymis in a 41 year old male patient, diagnosed by FNAC and confirmed by histopathology.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Genital Neoplasms, Male / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366111.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


28. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP: Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol; 2009 Mar;22(3):345-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently a candidate serous cancer precursor containing p53 mutations (p53 signature) was described in the fallopian tube.
  • In total 10 endometrial polyps involved by intraepithelial and/or invasive carcinoma and 137 benign polyps were studied.
  • Of 137 benign polyps (4%), 6 contained p53 signatures.
  • DNA damage (gamma-H2AX) was demonstrated in both p53 signatures and adjacent carcinomas but not in benign polyps.
  • The significance of p53 signatures in benign conditions (polyps) remains to be determined.
  • The role of the p53 signature in early serous neoplasia is discussed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):937-42 [18500258.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1467-71 [10550302.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Obstet Gynecol. 1987 Jan;69(1):109-13 [3796910.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):7-10 [16962648.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • (PMID = 19151662.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R21 CA124688-02; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / CA124688-02; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS77435; NLM/ PMC2649686
  •  go-up   go-down


29. Kanngurn S, Somran J, Art-Ong C, Lamlertthon W, Porncharoenpong S: Primary peritoneal adenosarcoma with stromal overgrowth and fetal type cartilage: a case report and literature review. J Med Assoc Thai; 2005 Jun;88(6):849-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor seems likely to have derived from the pelvic peritoneum, wheareas the uterus, ovaries and tubes were uninvolved.
  • It was composed of benign-appearing glands and a sarcomatous component showing cartilaginous differentiation.
  • The extrauterine adenosarcomas were reported in other sites, e.g. cervix, ovary, fallopian tube, bladder, and peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083229.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Number-of-references] 22
  •  go-up   go-down


30. Vaysse C, Capdet J, Mery E, Querleu D: Paratubal endometrioid cystadenocarcinoma: case report and review. Eur J Gynaecol Oncol; 2009;30(4):443-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Final pathology indicated a heterogeneous tumor with benign, borderline, and endometrioid carcinoma areas.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761142.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 11
  •  go-up   go-down


31. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Six developed metastases and 5 of them died of tumor.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Chang HC, Bhatt S, Dogra VS: Pearls and pitfalls in diagnosis of ovarian torsion. Radiographics; 2008 Sep-Oct;28(5):1355-68
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pearls and pitfalls in diagnosis of ovarian torsion.
  • Ovarian torsion is usually associated with a cyst or tumor, which is typically benign; the most common is mature cystic teratoma.
  • Common CT features of ovarian torsion include an enlarged ovary, uterine deviation to the twisted side, smooth wall thickening of the twisted adnexal cystic mass, fallopian tube thickening, peripheral cystic structures, and ascites.
  • [MeSH-major] Diagnostic Errors / prevention & control. Ovarian Diseases / diagnosis. Pregnancy Complications / diagnosis. Tomography, X-Ray Computed / methods. Torsion Abnormality / diagnosis. Ultrasonography / methods
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Pregnancy

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18794312.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Liu AX, Sun J, Shao WQ, Jin HM, Song WQ: Steroid cell tumors, not otherwise specified (NOS), in an accessory ovary: a case report and literature review. Gynecol Oncol; 2005 Apr;97(1):260-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: This 30-year-old woman had an accessory ovarian tumor attached to the infundibulum of the right fallopian tube which was solid and gross pathologically and microscopically showed the appearances of steroid cell tumor, NOS, a benign entity.
  • CONCLUSION: We report the first case of an accessory ovarian steroid cell tumor, NOS, which attached to the infundibulum of fallopian tube.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790472.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down






Advertisement